OBJECTIVE -To assess the predictive value of the metabolic syndrome in patients with type 1 diabetes.
T ype 1 diabetes is associated with an increased risk of cardiovascular morbidity and mortality, which is largely, but not totally, explained by the presence of diabetic nephropathy (1) . The metabolic syndrome, a cluster of cardiovascular risk factors, increases the risk of cardiovascular disease and chronic renal disease in the general population and in patients with type 2 diabetes (2-4). The metabolic syndrome is common in patients with type 1 diabetes (5-7), but its role as a predictor of cardiovascular disease and diabetic nephropathy is less clear (8, 9) . Therefore, the aim of this study was to assess the predictive value of the different definitions of the metabolic syndrome for cardiovascular events, cardiovascularand diabetes-related mortality, and the progression of renal disease in type 1 diabetes.
RESEARCH DESIGN AND
METHODS -All patients participated in the Finnish Diabetic Nephropathy (FinnDiane) Study, initiated in 1997.
The present study is prospective and includes 3,783 adult patients with type 1 diabetes from the FinnDiane Study, who at baseline had complete lipid profiles and data available on the components of the metabolic syndrome. A more detailed description of the baseline visit has previously been reported (5 (12) definitions (see supplementary Table A1 , available in the online appendix at http:// care.diabetesjournals.org/cgi/content/full/ dc08-2022/DC1). All patients with type 1 diabetes fulfilled the criteria for hyperglycemia.
Data on mortality were available for all patients, and death certificates were retrieved from Statistics Finland. Cardiovascular-and diabetes-related mortality was used as the end point, defined as underlying or immediate cardiovascular-or diabetes-related cause of death. Collection of follow-up data on morbidity is still ongoing; data on cardiovascular morbidity were available for 2,474 patients (65%) and data on progression of renal disease for 2,594 patients (69%). The data were collected from follow-up visits (36%) or medical files (64%). Progression of renal disease was defined as a change in category from normal UAER to microalbuminuria (n ϭ 118), microalbuminuria to macroalbuminuria (n ϭ 54), or macroalbuminuria to ESRD (n ϭ 130).
RESULTS -At baseline, the prevalence of MS WHO was 44%, MS NCEP 35%, and MS IDF 36%. The overlap of the three definitions is shown in Figure A1 in the online appendix. Detailed clinical charac- teristics of the patients are presented in Table A2 in the online appendix.
During median 5.5 years (interquartile range 3.7-6.7) of follow-up, 263 patients suffered a cardiovascular event; of these, 106 had a history of previous events and 173 had diabetic nephropathy at baseline. Figure A2 in the online appendix).
During a median 5.7 years (interquartile range 4.0 -6.9) of follow-up, 238 patients died from either cardiovascular-or diabetes-related causes. The predictive value of the metabolic syndrome on cardiovascular-and diabetes-related mortality is shown in Table 1 . Of individual components of the metabolic syndrome, all except obesity were independent predictors of cardiovascular-and diabetesrelated mortality. The predictive value of the metabolic syndrome on the progression of diabetic nephropathy is shown in CONCLUSIONS -Our main findings support data from two prospective studies on the role of the metabolic syndrome in type 1 diabetes (8, 9) . Of the current definitions, MS WHO is associated with the highest risk of cardiovascular outcomes, followed by MS NCEP , whereas MS IDF is the weakest predictor. Diabetic nephropathy is accompanied by the metabolic syndrome (5) and is also the strongest risk factor for cardiovascular outcomes in patients with type 1 diabetes. In the present study, most of the cardiovascular events were seen in those with diabetic nephropathy. Taking these facts into consideration, it is difficult to eliminate diabetic nephropathy where the role of the metabolic syndrome is assessed. The independent risk shown for MS WHO on cardiovascular events and cardiovascular-and diabetes-related mortality, adjusted for diabetic nephropathy, suggests that the metabolic syndrome plays an independent role. It could, however, be argued that the effect is due to the inclusion of microalbuminuria in the MS WHO . We were, however, also able to show an additional effect of MS NCEP beyond elevated UAER alone, suggesting a true role of the metabolic syndrome as a risk factor for cardiovascular outcomes. The results from the present and earlier studies suggest that the role of the metabolic syndrome on progression to microalbuminuria is modest, whereas at later stages the metabolic syndrome plays a larger role.
Of the individual components, abdominal obesity seems to play the weakest role. This is surprising because abdominal obesity is a key feature of insulin resistance, an established risk factor for cardiovascular disease (13) . However, all the other individual components were independent predictors of both cardiovascular events and cardiovascular-and diabetes-related mortality. In patients on dialysis, obesity has been associated with better survival (the obesity paradox), highlighting the importance of optimal nutrition (14) . In the present study, MS IDF obesity was seemingly protective of progression to ESRD, suggesting an inverse or U-shaped relationship in patients with macroalbuminuria.
A major limitation was the incomplete follow-up data on mortality, which was due to the ongoing nature of the FinnDiane Study. In conclusion, the metabolic syndrome is an independent risk factor for cardiovascular events and adds to the risk related to albuminuria. No potential conflicts of interest relevant to this article were reported.
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